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Key points 
 
• Germline loss-of-function mutations in shelterin genes occur in a subset of families with 
CLL 
• Telomere dysregulation is further implicated in CLL predisposition 
 
 
Abstract 
 
Chronic lymphocytic leukemia (CLL) can be familial, however thus far no rare germline disruptive 
alleles for CLL have been identified. We performed whole-exome sequencing of 66 CLL families, 
identifying four families where loss-of-function mutations in POT1 co-segregated with CLL. The 
p.Tyr36Cys mutation is predicted to disrupt the interaction between POT1 and the telomeric 
overhang. The c.1164-1G>A splice-site, p.Gln358SerfsTer13 frameshift and p.Gln376Arg missense 
mutations are likely to impact the interaction between POT1 and ACD, part of the telomere-
capping shelterin complex. We also identified mutations in ACD (c.752-2A>C) and another 
shelterin component, TERF2IP (p.Ala104Pro and p.Arg133Gln), in three CLL families. In a 
complementary analysis of 1,083 cases and 5,854 controls, the POT1 p.Gln376Arg variant, which 
has a global minor allele frequency of 0.0005, conferred a 3.61-fold increased risk of CLL (P=0.009). 
This study further highlights telomere dysregulation as a key process in CLL development. 
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Introduction 
 
Chronic lymphocytic leukemia (CLL; MIM151400) is clinically defined by the presence of a clonal 
population of B-cell lymphocytes (>5 ×10
9
 cells/L) with a characteristic immunophenotype. The 
disease accounts for approximately 25% of all leukemia and is the most common form of lymphoid 
malignancy in Western countries, affecting around 16,000 individuals in the United States each 
year
1
. While the last decade has seen a dramatic evolution in the treatment options for CLL
2-4
, it 
still remains an incurable malignancy. It is anticipated that an increased understanding of CLL 
pathogenesis will generate further therapeutic targets to either delay or prevent progression of 
the precursor to frank malignancy.  
CLL has one of the highest familial risks of any cancer, with risk being increased eight-fold in 
relatives of patients
5
. Recent genome-wide association studies (GWAS) have identified common 
risk single nucleotide polymorphisms (SNPs) at 31 loci associated with sporadic CLL
6-13
.  The risk of 
CLL associated with each of these variants is however modest at best. While families segregating 
CLL provide evidence for Mendelian susceptibility, no rare alleles of large effect have thus far been 
discovered. The identification of this class of susceptibility is especially important since mutations 
are causal and provide direct insight to cancer biology, in contrast to GWAS associations. 
Here we report on the whole exome sequencing of familial CLL and establish a key role for rare 
disruptive mutations in POT1 and other shelterin complex genes as determinants of susceptibility 
to CLL. Our findings thus extend the spectrum of cancer types associated with germline mutation 
in these genes.  
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Materials and methods 
 
Patient samples and DNA extraction 
The families and CLL cases included in this study were recruited through a UK national study of CLL 
genetics established by the Institute of Cancer Research Divisions of Genetics and Epidemiology 
and Molecular Pathology in 1996. The diagnosis of CLL and other haematological cancers in family 
members were established. In all cases the diagnosis of CLL was based on accepted standard 
clinico-pathological and immunological criteria that are in accordance with current World Health 
Organization classification guidelines. Informed consent was obtained under MREC 99/1/082. 
Genomic DNA was extracted from peripheral blood and saliva using standard methods and 
quantified by PicoGreen (Invitrogen). 
 
Pedigrees and clinical presentation 
Supplemental Table 1 details all pedigrees, the number of cases of CLL in each family, and the 
number of cases that were whole-exome sequenced.  
 
Sequence alignment and analysis   
Exon capture was performed using the Nextera Rapid Capture Exome Enrichment kit (Illumina, San 
Diego, CA, USA). The Illumina HiSeq2000 analyser with 101 base pair reads was used for 
sequencing. Paired-end fastq files were extracted using CASAVA software (version 1.8.1, Illumina) 
and aligned to build 37 (hg19) of the human reference genome using Stampy
14
 and BWA
15
 
software. Alignments were processed using the Genome Analysis Tool Kit (GATK) pipeline (version 
3.2-2)
16
, according to best practices
17,18
. Variants were filtered for positions found in >1 sample 
from an in-house collection of 1,609 control exomes including; 961 samples from the ICR1000 
dataset generated by Professor Nazneen Rahman’s Team in the Division of Genetics & 
Epidemiology at The Institute of Cancer Research, London
19
 plus an extra 648 samples from the UK 
1958 Birth Cohort (BC)
20
, sequenced in-house using Illumina TruSeq exome methodology. We also 
filtered variants based on frequencies in the 1000 Genomes Project, National Heart, Lung and 
Blood Institute Exome Sequencing Project (ESP6500) and the Exome Aggregation Consortium 
(ExAC) catalog. Positions resulting in protein-altering changes were identified using the Ensembl 
Variant Effect Predictor (version 78) and variants shared between family members were annotated 
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using custom scripts.  The predicted functional consequences of missense variants were assessed 
using SIFT
21
, CADD
22
 and SuSPect
23
 algorithms.  
 
Sanger Sequencing 
Germline verification of variants found by next generation sequencing was performed by Sanger 
sequencing of mouthwash DNA samples.  Primers are listed in Supplemental Table 2. 
 
MaxEntScan scoring of splice acceptor variants  
We used the MaxEntScan algorithm
24
 to assess the effect of POT1 g.124481233C>T and ACD 
g.67692984T>G mutations. Scores for the mutated splice acceptor site and wild-type splice site 
sequence were 5.66, -3.08 and 9.88, 1.84 respectively. 
 
Confirmation of aberrant splicing in an individual carrying the splice acceptor variant 
7:g.124481233C>T 
RNA extracted from the whole blood of a splice acceptor variant carrier and control was converted 
to cDNA using Superscript III Reverse Transcriptase (Invitrogen). PCR was then performed to 
confirm that 7:g.124481233C>T disrupted splicing. The product was visualized on a 2.5% agarose 
gel.  Sanger sequencing was used to confirm the sequence of the product. 
 
Exome array genotyping 
1,111 unrelated CLL cases were genotyped for the p.Gln376Arg variant using the Illumina 
OmniExpress Exome array as previously described
12
. After quality control filtering, genotype data 
were available for 1,083 CLL cases.  For controls, we used publicly accessible data for 5,854 
individuals from the 1958 Birth Cohort
20
 genotyped using the Illumina HumanExome-12v1 array. 
These data are available from the European Genome-phenome Archive (EGA) under accession 
number EGAD00010000234. The chi-squared test was used to determine the significance of the 
difference in case-control allele counts. Confidence intervals were calculated by the Woolf 
method. 
 
Protein alignment and structural modelling  
Multiple sequence alignments were generated for homologous POT1 and TERF2IP protein 
sequences using T-Coffee
25,26
 to evaluate conservation. POT1 alignments were generated with the 
following sequences: NP_056265.2, XP_519345.2, NP_001127526.1, XP_009001386.1, 
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XP_006149256.1, NP_598692.1, XP_002712135.2, XP_010802750.1, XP_005628494.1, 
XP_001501458.4, XP_006910616.1, XP_010585693.1, XP_004478311.1, XP_007504310.1, 
XP_001508179.2, NP_996875.1 and NP_001084422.1. TERF2IP alignments were generated with 
the following sequences: NP_061848.2, NP_001267142.1, XP_003780774.2, XP_008984478.1, 
XP_006152679.1, NP_065609.2, XP_002711780.1, NP_001068880.1, XP_536776.2, 
XP_005608497.1, XP_006908867.1, XP_010595146.1, XP_004470975.1, XP_001508762.2, 
NP_989799.1 and NP_001084428.1. Jalview
27
 was used to visualize and format the alignments.  
The crystal structure of the N-terminal region (OB1 and OB2 domains) of the human POT1 protein 
(RCSB PDB, 3KJP and 1XJV) was visualized using Chimera (version 1.10.2)
28
 and Cn3D (version 
4.3.1)
29
. The impact of the p.Tyr36Cys mutation on stability of the POT1:DNA interaction was 
assessed using mCSM
30
.  The effect of missense mutations on protein stability was assessed using 
INPS
31
.  
 
Loss-of-heterozygosity analyses 
Loss-of-heterozygosity (LOH) analysis was conducted using ExomeCNV
32
 which detects copy 
number variation (CNV) and LOH events using depth-of-coverage and B-allele frequencies. LOH 
calls were made by first identifying all heterozygous germline positions. GATK was then used to 
create BAF files and ExomeCNV used to call LOH at heterozygous positions individually and at 
combined LOH segments.   
 
Assessment of telomere length  
Relative telomere length was determined by two methods: using exome sequencing data and with 
real-time PCR.  Analysis of off-target reads from exome sequencing data was performed essentially 
as described
33
, using a telomeric repeat copy number of k=4.  We used data from blood-derived 
DNA only and also excluded samples with average sequencing depth <20 and with missing 
covariate data (n=12).  Telomere length was adjusted for age at blood draw, sex and sequencing 
batch by a linear model determined using data from non-carriers only. For the SYBR green real-
time PCR, the ratio of telomere repeat units to a single-copy gene (β-globin) for 109 samples, was 
determined as previously described
34,35
. Primers are listed in Supplementary Table 2.  Reactions 
were performed in triplicate, using 10ng DNA per sample. Each 10μL reaction also contained 5μL 
of 2X SYBR Green Master Mix (Applied Biosystems) plus either 300 and 700 nmol/L of the control 
forward and reverse primers, respectively or 100 and 900 nmol/L of the telomere unit forward and 
reverse primers, respectively.  The telomere reaction also included 0.3μL DMSO. Cycling was 
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performed using an ABI7900HT thermal cycler as previously described
35
. Relative telomere length 
was calculated using 2
−ΔCt
 derived from the real-time PCR data and was adjusted for age at blood 
draw and sex. A Wilcoxon rank-sum test was used to compare the relative adjusted telomere 
length for POT1 mutation carriers versus non-carriers of shelterin gene mutations. 
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Results 
 
Identification of shelterin gene mutations  
To maximise the prospects of identifying rare disease-causing variants for CLL we initially focussed 
our search on the 18 families with the strongest family histories of CLL (Supplemental Table 1) 
which had been ascertained through an ongoing study
36
. We performed whole exome sequencing 
on genomic DNA from blood of 45 affected individuals from the 18 families. We excluded variants 
that were observed more than once in our in-house database of 1,609 healthy individuals from the 
1958 BC who had been exome sequenced. We also discounted variants with an allele frequency of 
greater than 0.1% in large-scale sequencing projects (1000 Genomes Project, ESP6500 or the ExAC 
catalog). In our first stage analysis we required the filtered variants to be present in all sequenced 
affecteds within the family.  
 
To further filter the variants identified, we prioritised missense and disruptive variants (nonsense, 
splice acceptor/donor and frameshift) occurring in genes with a reported cancer association or 
documented role in cancer predisposition. Analysis of these genes led us to identify pedigree 5047 
in which all three affected family members carried a splice acceptor variant in intron 13 
(chromosome 7 g.124481233C>T/c.1164-1G>A) of POT1 (protection of telomeres 1; MIM 606478) 
(Figure 1 and 2a). We confirmed the mutation by Sanger sequencing in blood and saliva derived 
DNA in all three cases (Supplemental Figure 1). The mutation was predicted to disrupt splicing by 
the MaxEntScan algorithm
24
 (wild-type score 5.66 versus mutated score -3.08, 154% reduction). 
This also identified a potential alternative splice acceptor site 43bp downstream (MaxEntScan 
score=7.66), the use of which would result in a truncated protein product.  We confirmed the 
presence of an aberrant splicing product in a mutation carrier by RT-PCR and validated the use of 
the predicted alternative splice site using Sanger sequencing (Figure 3, Supplemental Figure 2). 
 
To further investigate the potential role of POT1 and other members of the shelterin gene 
complex in familial CLL, we expanded our exome sequencing dataset to include an additional 96 
affected relative-pairs from 48 families (Supplemental Table 1). We then looked for shared 
missense and disruptive variants in the six components of the shelterin complex (POT1, ACD, 
TINF2, TERF1, TERF2 and TERF2IP). Through this analysis we identified three additional families 
that harbored POT1 mutations (Figure 1); two missense mutations, p.Tyr36Cys and p.Gln376Arg, 
occurring at evolutionarily conserved residues (Figure 2b), predicted in silico to be damaging by 
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multiple algorithms, and a frameshift mutation (Table 1). Collectively, we therefore identified 
mutations in POT1 in 6% of the CLL families, as compared with the documented frequency of such 
variants of only 0.9% amongst the 60,706 individuals included in the ExAC catalog (P=0.003).   
 
Intriguingly, somatic mutations of residue Tyr36 have previously been reported in CLL (Figure 
2a)
37-39
. The p.Gln376Arg variant, identified in pedigree 4013, has a global minor allele frequency 
(MAF) of 0.0005 in the ESP6500 database and is included on the Illumina Exome array. We 
therefore initiated a genetic association study of this recurrent variant making use of Illumina 
exome array data on 1,083 unselected CLL cases and 5,854 1958 BC controls. Six of the cases and 
nine of the controls were heterozygous for the p.Gln376Arg variant (odds ratio, OR=3.61, 95% 
confidence interval: 1.28-10.15, P=0.009).  
 
In addition to POT1 mutations, we identified mutations in other shelterin complex genes in 
families 233, 4092 and 4014. Specifically, the ACD (adrenocortical dysplasia protein homolog, MIM 
609377) splice site variant c.752-2A>C was carried by both affected siblings in pedigree 233 (Figure 
1, Supplemental Figure 3a) and was predicted by the MaxEntScan algorithm to disrupt the exon 7 
splice acceptor signal (wild-type score 9.88 versus mutated score 1.84, 81% reduction, 
Supplemental Figure 3b).  In TERF2IP (telomeric repeat binding factor 2, interacting protein, MIM 
605061), the missense mutation c.398G>A (p.Arg133Gln) was identified in two out of three CLL 
cases sequenced in family 4014 (Figure 1, Supplemental Figure 4a).  This mutation occurs at an 
evolutionarily conserved site and was predicted to be damaging by multiple methods (Table 1, 
Supplemental Figure 4b).  We also found the c.310G>C (p.Ala104Pro) TERF2IP variant in both 
siblings in family 4092 (Figure 1, Table 1, Supplemental Figure 4a). While this residue is partially 
conserved, the p.Ala104Pro mutation is not predicted to be damaging by SIFT or SuSPect (Table 1, 
Supplemental Figure 4b).   
 
Structural predictions 
The POT1 N-terminus contains two oligonucleotide/oligosaccharide binding (OB) folds that bind to 
the single-stranded telomeric overhang (Figure 2) while the C-terminus is responsible for binding 
to ACD and anchoring the shelterin complex. The crystal structure of human POT1 has been 
resolved for only the N-terminal OB-folds (Protein Data Bank (PDB) 3KJP and 1XJV).  Based upon 
these structures, Tyr36 is one of 24 residues found at the POT1:telomeric polynucleotide 
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interface
39
 (Figure 2).  The p.Tyr36Cys mutation is predicted by mCSM to reduce the POT1:DNA 
complex affinity (PDB 1XJV, ΔΔG -0.27Kcal/mol; PDB 3KJP, predicted ΔΔG -0.21Kcal/mol).  
 
Since crystal structures for full-length POT1 and TERF2IP are lacking, we used the machine learning 
algorithm INPS to predict the thermodynamic change in free energy caused by the p.Gln376Arg 
(POT1), p.Ala104Pro and p.Arg133Gln (TERF2IP) mutations, based upon the protein sequence 
(Supplemental Table 3). Using this method p.Arg133Gln was predicted to have the largest effect 
upon protein stability. 
 
Analysis of somatic events 
We used ExomeCNV to look for evidence of LOH in the proband of pedigree 5047, comparing 
exome sequencing data from blood-derived DNA to saliva-derived DNA, finding no evidence of a 
somatic abnormality at the POT1 locus.  We also looked for deleterious variants identified only in 
the blood-derived DNA of this case (i.e. absent from the saliva-derived DNA sample and also 
absent from the other affected individuals in pedigree 5047) and found no somatic inactivating 
POT1 mutations. We did however note the presence of a somatic splice donor site mutation 
affecting the first base of intron 10 of ATR (ataxia-telangiectasia and rad3-related) in this case. 
 
Effect of POT1 mutations on maintenance of telomere length  
Given the role of the shelterin complex in telomere length maintenance we examined whether CLL 
cases from shelterin-mutated pedigrees had telomere lengths that differed from non-carrier CLL 
cases using exome sequencing and real-time PCR data. We observed no consistent significant 
difference between the telomere lengths of POT1 mutation carriers and CLL cases without a 
mutation in a shelterin complex gene, by exome sequencing or real-time PCR (P=0.03/P=0.57, 
respectively). The telomere lengths of cases with ACD or TERF2IP variants also displayed no 
obvious trend, although the small numbers of cases harbouring these variants precluded a 
meaningful evaluation of their impact on telomere length. 
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Discussion 
 
Here we have implemented whole exome sequencing to search for rare disruptive risk alleles for 
CLL, identifying germline-inactivating shelterin gene mutations in a subset of CLL families. These 
findings are consistent with the evidence of linkage of familial CLL to chromosomes 7q31.32-q33 
and 16q12.2-q23.1 that we previously observed (Supplemental Figure 5)
40
.  
 
Germline disruptive variants within shelterin genes have recently been implicated in 
predisposition to familial melanoma
41,42
, cardiac angiosarcoma
43
, glioma
44
 and colorectal cancer
45
, 
whilst somatic mutations of POT1 are detectable in 3.5% of all CLL and 9% of IGHV (encoding 
immunoglobulin heavy chain variable)-unmutated CLL
39
 and were also identified in 10% of 
patients with cutaneous T cell lymphoma
46
. 
 
POT1-mutated CLL cells have numerous telomeric and chromosomal abnormalities, suggesting 
that POT1 mutation facilitates the acquisition of these malignant features
39
. Our observation of 
germline mutations in POT1 being associated with familial CLL would concur with this assumption. 
Our findings also support the proposal that POT1 mutation is an early event in CLL development
37
 
In a CLL GWAS we previously reported an association between the common allele of the POT1 
3’UTR variant rs17246404 (risk allele frequency=0.75) and increased CLL risk, with a small per 
allele effect size (OR=1.22)
12
. The recurrent POT1 coding variant, p.Gln376Arg, identified in the 
current study is not however in linkage disequilibrium with SNP rs17246404 (r
2
=0.00). Therefore, 
although further studies are required to determine exactly how rs17246404 influences CLL risk, it 
is plausible that the functional basis of the association is through differential gene expression.  
 
Shelterin is a telomere-specific protein complex composed of six family members, encoded by 
POT1, ACD, TERF2IP, TERF1 (encoding telomeric repeat binding factor 1), TERF2 (encoding 
telomeric repeat binding factor 2) and TINF2 (encoding TERF1 interacting nuclear factor 2), that 
protects the ends of chromosomes. Together, the components of the shelterin complex are 
necessary for all telomere functions, including the protection of telomeres from degradation, 
aberrant recombination and incorrect processing by DNA-repair machinery as well as facilitating 
chromosome capping to mediate telomerase activity
47
.  
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POT1 directly contacts telomeric DNA overhangs
48
 and also binds to ACD
49
 which connects POT1 to 
the other shelterin components via its bridge with TINF2
50
. The POT1:ACD interaction enhances 
the affinity of POT1 for telomeric DNA
49,51
. The ACD splice site mutation c.752-2A>C, will disrupt 
the POT1 binding domain and abolish the TINF2 binding domain, so would therefore be predicted 
to result in an unformed shelterin complex.  
 
In silico predictions suggest that the germline p.Tyr36Cys mutation identified in pedigree 162 is 
likely to disrupt the interaction between POT1 and the single-stranded telomeric DNA overhang.  
The POT1 frameshift and splice site mutation are likely to result in truncated protein products, 
impairing their interaction with ACD.  The p.Gln376Arg variant, though not predicted in silico to 
impact protein stability, alters an evolutionarily constrained residue thus implying functional 
importance.  
 
Previous experiments have shown that when the ACD/POT1 subunit is inhibited, the telomerase 
complex increases telomere length
48,50
.  We observed no significant differences between the 
telomere lengths of CLL cases with a POT1 mutation and those who did not harbour a shelterin 
gene mutation. This observation is comparable to that in tumor cells derived directly from CLL 
cases with a somatic POT1 mutation versus matched cases with no POT1 mutation
39
 and may 
reflect the numerous unmeasured variables that can influence telomere length in human 
populations.  We also acknowledge that our telomere length measurements are based on blood-
derived DNA and therefore could be subject to the effects of uncharacterized somatic mutations.  
In this regard, we note that the proband of pedigree 5047 harbored a somatic splice site mutation 
in ATR, a gene also know to play a key role in telomere maintenance
52
. Furthermore, whilst GWAS 
have identified SNPs at loci including other telomere maintenance genes that are associated with 
telomere length, there has been no such association reported for a POT1 SNP
12,53,54
.    
 
TERF2IP associates with the shelterin complex via its C-terminus to a central region of TERF2, 
forming a stable 1:1 complex. TERF2IP, as part of the shelterin complex, is vital for the repression 
of homology-directed repair of double strand chromosomal break at the telomere. While the 
novel missense variant p.Arg133Gln is predicted to be pathogenic, markedly reducing the stability 
of the protein, p.Ala104Pro is less well conserved and is thus more likely to be tolerated
40
.  
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Germline disruptive mutations in POT1 have previously been associated with susceptibility to 
melanoma in nine families
41,42
 and glioma in three families
44
. Furthermore, recent studies have 
identified POT1 p.Arg117Cys in four Li-Fraumeni-like syndrome families
43
, and ACD and TERF2IP 
mutations in eight melanoma families
55
. None of the mutation carriers in the melanoma families 
featured cases of glioma or CLL. Similarly, the glioma families did not feature cases of melanoma 
or CLL and the only case of melanoma was seen in one of the Li-Fraumeni-like syndrome families. 
Collectively these data, and the fact that none of our families segregated glioma or melanoma, 
suggest that the penetrance associated with rare shelterin complex mutations is modest. Such an 
assertion is supported by our observation that the predicted deleterious p.Arg133Gln TERF2IP 
variant was identified in only two out of three CLL cases sequenced in family 4014.  Additionally, in 
our case-control analysis, the POT1 p.Gln376Arg mutation was shown to confer a modest 3.6-fold 
increase in risk of CLL. Furthermore, the absence of significant loss-of-heterozygosity in the tumors 
of carriers, when examined
43
, suggests mutations in the shelterin complex genes do not function 
as high penetrance tumor suppressors, but rather moderate penetrance alleles.  
 
Early age of onset in cancer can be indicative of inherited predisposition and it is noteworthy that 
in this study, mutation carriers were diagnosed with CLL much younger than the population 
average (59 years as compared to 71 years). Since seven of the 66 CLL families were carriers of 
shelterin mutations, this translates to 11% of familial CLL being ascribed to mutations in this class 
of genes (95% confidence interval, 4%–21%). However, we acknowledge that our analyses were 
based only on families ascertained in the UK and therefore the impact of such mutations on 
familial CLL could vary depending on ethnicity. Moreover, it remains to be established, through 
additional studies, whether other CLL families are the consequence of polygenic susceptibility or 
as yet unidentified higher impact disease-causing mutations.  
 
In summary, the POT1, ACD and TERF2IP loss-of-function mutations we report here suggest that 
multiple components of the shelterin complex play a role in CLL predisposition. Moreover, they 
extend the spectrum of cancer associated with inherited mutations in these genes. It is however, 
likely that shelterin complex gene mutations confer cancer risks analogous to those associated 
with ATM heterozygosity
56
 or CHEK2
57
 for breast cancer. Nevertheless, since the dysregulation of 
telomere protection has been identified as a target for potential therapeutic intervention in CLL, it 
may be possible that early identification of mutation carriers will facilitate improvements in future 
disease management.  
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Table 1. Germline mutations in shelterin complex genes identified in CLL pedigrees 
 
Gene 
Mutation position    Effect predictions  
Genomic (hg19) cDNA
a
 Protein Variant type Pedigree Carriers
b
 CADD
c
 SIFT SuSPect
d
 GERP 
POT1 7:g.124481233C>T c.1164-1G>A na Splice acceptor 5047 3 / 3 / 3 17.16 na na 4.67 
POT1 7:g.124532337T>C c.107A>G p.Tyr36Cys Missense 162 2 / 2 / 2 18.9 Deleterious 71 5.71 
POT1 7:g.124482952_124482953insA c.1071_1072insT p.Gln358SerfsTer13 Frameshift 4029 2 / 2 / 4 na na na 4.71 
POT1 7:g.124482897T>C c.1127A>G p.Gln376Arg Missense 4013 2 / 2 / 3 23 Deleterious 50 5.55 
ACD 16:g.67692984T>G c.752-2A>C na Splice acceptor 233 2 / 2 / 2 19.35 na na 5.15 
TERF2IP 16:g.75682090G>C c.310G>C p.Ala104Pro Missense 4092 2 / 2 / 3 10.15 Tolerated 10 2 
TERF2IP 16:g.75682178G>A c.398G>A p.Arg133Gln Missense 4014 2 / 3 / 3 14.88 Deleterious 73 5.34 
na = not applicable; GERP= Genomic Evolutionary Rate Profiling score 
a 
POT1 reference transcript is NM_015450 and ACD reference transcript is NM_001082486 
b 
Carriers given as number of familial cases with mutation / number of cases in family exome sequenced / total number of CLL cases in family 
c
 CADD Phred-like score 
d
 Scores of 50 and above considered to indicate deleterious mutations 
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Figure legends 
 
Figure 1. Rare POT1, ACD and TERF2IP mutations in chronic lymphocytic leukemia families. Black 
filled symbols indicate CLL cases, other cancers are indicated by a blue filled symbol and an 
unfilled symbol indicates an individual with no known cancer. These symbols have a central dot to 
indicate cases who were exome sequenced. A central orange dot denotes a shelterin gene 
mutation carrier; a pink dot denotes a wild-type individual. A line through a symbol indicates that 
an individual is deceased. Age of diagnosis (in years) is listed for CLL cases. Splice acceptor variants 
are numbered relative to POT1 transcript NM_015450 and ACD transcript NM_001082486. NHL= 
non-Hodgkin lymphoma. 
 
Figure 2. Impact of rare familial mutations on POT1 protein 
(A) Schematic showing position of germline POT1 mutations identified in CLL families relative to 
OB domains (orange) and ACD binding region (blue). Also shown are somatic POT1 mutations 
identified in previous studies of CLL patients
39,58
 (unshaded background) and germline mutations 
found in familial cutaneous melanoma
41,42
 (yellow background). 
(B) Cross-species conversion of POT1 amino acids subject to missense mutation in CLL families.  
(C) Schematic of the crystal structure of human POT1 N-terminal OB-domains bound to a telomeric 
DNA sequence (Protein Data Bank 3KJP), illustrating the proximity of tyrosine 36 to the DNA 
strand. OB-domains are shown in grey, DNA is illustrated in blue and Tyr.36 is highlighted in pink. 
 
Figure 3. Impact of POT1 splice acceptor site mutation on splicing 
(A) Splice acceptor site consensus scores predicted by MaxEntScan
24
 for each base from the 
natural POT1 intron 13/exon 14 boundary across exon 14. For clarity, only part of the intron (lower 
case text above black line) and exon (upper case text above black box) are shown. The predicted 
score for the unmutated natural splice site (pink bar) is also labelled. Positive scores are otherwise 
marked in green, negative scores in orange.   
(B) MaxEntScan splice acceptor consensus scores for the same region based upon the sequence of 
c.1164-1G>A POT1 mutation carriers. The scores of the mutated natural splice acceptor (pink bar) 
and the predicted alternative splice site with the highest MaxEntScan score (43bp downstream) 
are labelled. The part of exon 14 that would be removed by use of this splice site is indicated by a 
grey box. 
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(C) Abnormal splicing product detected by RT-PCR using cDNA from a CLL case (Ca) carrying the 
c.1164-1G>A mutation.  This product is absent from control (Co) cDNA.  (NT=no template reaction, 
L=ladder, bp=base pairs). 
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